Characterizing the concentration and binding affinity of WT–induced antibodies against the Omicron subvariant BA.1

FHS
July 25, 2023
8:52 am

A recent study characterized the concentration and binding affinity of antibodies induced by SARS-CoV-2 WT strain against the Omicron subvariant BA.1.

Almirall and Microsoft partner for dermatological drug development

Share this article The collaboration aims to expedite the development of new dermatological treatment options. Credit: Kmpzzz / Shutterstock.com. Pharmaceutical company Almirall has entered a

February 1, 2024

STRIDE Regimen Shows Manageable Safety in Unresectable Liver Cancer

The use of single tremelimumab (Imjudo) and regular interval durvalumab (Imfinzi; STRIDE regimen) in patients with unresectable hepatocellular carcinoma (HCC) showed manageable and low-grade immune-mediated

July 8, 2023

Three Trials Examine Dupilumab in Moderate-to-Severe Asthma

Three abstracts evaluating dupilumab (Dupixent) for moderate-to-severe asthma were presented at the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting: VESTIGE, a

March 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.